<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887783</url>
  </required_header>
  <id_info>
    <org_study_id>09.01</org_study_id>
    <nct_id>NCT00887783</nct_id>
  </id_info>
  <brief_title>Navelbine And Radiotherapy in Locally Advanced Lung Cancer</brief_title>
  <acronym>NARLAL</acronym>
  <official_title>Induction Chemotherapy With Carboplatin and Navelbine Oral(R) Followed by Concomitant Navelbine Oral(R) and Irradiation in Local-regionally Advanced Non-small Cell Lung Cancer. A Randomized Phase II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen University Hospital at Herlev</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open label randomized multi-centre phase II trial in patients with&#xD;
      inoperable locally advanced stage IIB-IIIB Non Small Cell Lung Cancer who fulfils the general&#xD;
      criteria for curatively intended irradiation. The treatment plan consists of two courses of&#xD;
      inductions chemotherapy followed of concomitant therapy chemo-radiotherapy 3 weeks after day&#xD;
      1 of the last induction chemotherapy has been given. The patients will be included in the&#xD;
      study after completing the induction chemotherapy. Randomization will take place only if an&#xD;
      acceptable dose plan can be obtained.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was an open label randomized multi-centre phase II trial in patients with&#xD;
      inoperable locally advanced stage IIB-IIIB Non Small Cell Lung Cancer who fulfils the general&#xD;
      criteria for curatively intended irradiation. The treatment plan consisted of two courses of&#xD;
      inductions chemotherapy followed of concomitant therapy chemo-radiotherapy 3 weeks after day&#xD;
      1 of the last induction chemotherapy has been given. The patients was included in the study&#xD;
      after completing the induction chemotherapy. Randomization took place only if an acceptable&#xD;
      dose plan could be obtained.&#xD;
&#xD;
      Primary endpoint: local recurrence free interval&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2009</start_date>
  <completion_date type="Actual">September 1, 2016</completion_date>
  <primary_completion_date type="Actual">September 1, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No blinding after randomization</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Local Failure Free Survival</measure>
    <time_frame>9 months</time_frame>
    <description>Local failure free survival 9 month after first RT treatment measured by CT/FDG-CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Early Toxicity to Concurrent Vinorelbine and Radiotherapy</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Tumour Control</measure>
    <time_frame>9 months</time_frame>
    <description>Loco-regional control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>72 months</time_frame>
    <description>Overall survival, death of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Toxicity</measure>
    <time_frame>36 months</time_frame>
    <description>Late toxicity related to concurrent Vinorelbine and radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>72 months</time_frame>
    <description>Disease free survival, death of any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>B: 66Gy/33F+Navelbine oral 150 mg q3w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks).&#xD;
Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A: 60Gy/30F+Navelbine oral 150 mg q3w</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks) Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Navelbine</intervention_name>
    <description>Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks</description>
    <arm_group_label>A: 60Gy/30F+Navelbine oral 150 mg q3w</arm_group_label>
    <arm_group_label>B: 66Gy/33F+Navelbine oral 150 mg q3w</arm_group_label>
    <other_name>Vinorelbine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>66 Gy/33F</intervention_name>
    <description>irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)</description>
    <arm_group_label>B: 66Gy/33F+Navelbine oral 150 mg q3w</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>60 Gy/30F</intervention_name>
    <description>irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)</description>
    <arm_group_label>A: 60Gy/30F+Navelbine oral 150 mg q3w</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Patients with histologically or cytologically documented diagnosis of locally advanced&#xD;
             NSCLC stage IIB to IIIB without pleural effusion&#xD;
&#xD;
          -  Performance status 0-1 on the ECOG scale&#xD;
&#xD;
          -  Weight loss ≤10% during the last 6 months&#xD;
&#xD;
          -  Adequate lung function measured as FEV1 ≥1.0&#xD;
&#xD;
          -  Neutrophile count ≥1.5 x 109/L and platelet count ≥100 x 109/L&#xD;
&#xD;
          -  Serum bilirubin ≤1.5 upper limit of normal (ULN)&#xD;
&#xD;
          -  ALAT ≤2 x ULN&#xD;
&#xD;
          -  Able to comply with study and follow-up procedures&#xD;
&#xD;
          -  Patients with reproductive potential must use effective contraception&#xD;
&#xD;
          -  Written (signed) informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any unstable systemic disease (including active infection, unstable angina, congestive&#xD;
             heart failure, severe hepatic, renal, or metabolic disease)&#xD;
&#xD;
          -  Any other active malignancies within 5 years (except for adequately treated carcinoma&#xD;
             in situ of the cervix or basal or squamous cell skin cancer)&#xD;
&#xD;
          -  Prior chemotherapy for lung cancer, including neo- and adjuvant chemotherapy&#xD;
&#xD;
          -  Inability to take oral medication, or requirement of intravenous alimentation&#xD;
&#xD;
          -  Active peptic ulcer disease&#xD;
&#xD;
          -  Nursing mothers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olfred Hansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Copenhagen University Hospital Herlev</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laboratory of Radiation Physics</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <results_reference>
    <citation>Hansen O, Knap MM, Khalil A, Nyhus CH, McCulloch T, Holm B, Brink C, Hoffmann L, Schytte T. A randomized phase II trial of concurrent chemoradiation with two doses of radiotherapy, 60Gy and 66Gy, concomitant with a fixed dose of oral vinorelbine in locally advanced NSCLC. Radiother Oncol. 2017 May;123(2):276-281. doi: 10.1016/j.radonc.2017.03.017. Epub 2017 Apr 11.</citation>
    <PMID>28410809</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>April 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2009</study_first_posted>
  <results_first_submitted>July 21, 2017</results_first_submitted>
  <results_first_submitted_qc>January 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 8, 2021</results_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Olfred Hansen</investigator_full_name>
    <investigator_title>MD, Professor</investigator_title>
  </responsible_party>
  <keyword>Induction chemotherapy</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Randomized phase II study</keyword>
  <keyword>Navelbine Oral (R)</keyword>
  <keyword>3D-conformal radiotherapy</keyword>
  <keyword>Chemo-radiotherapy</keyword>
  <keyword>Local-regionally advanced non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Further studies on toxicity profiles and PET may be performed</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>117 included July 2009 to August 2013</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>B: 66Gy/33F+Navelbine Oral 150 mg q3w</title>
          <description>Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks).&#xD;
Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization&#xD;
Navelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks&#xD;
66 Gy/33F: irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)</description>
        </group>
        <group group_id="P2">
          <title>A: 60Gy/30F+Navelbine Oral 150 mg q3w</title>
          <description>Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks) Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization&#xD;
Navelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks&#xD;
60 Gy/30F: irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>B: 66Gy/33F+Navelbine Oral 150 mg q3w</title>
          <description>Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks).&#xD;
Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization&#xD;
Navelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks&#xD;
66 Gy/33F: irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)</description>
        </group>
        <group group_id="B2">
          <title>A: 60Gy/30F+Navelbine Oral 150 mg q3w</title>
          <description>Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks) Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization&#xD;
Navelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks&#xD;
60 Gy/30F: irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="117"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="58"/>
                    <count group_id="B2" value="59"/>
                    <count group_id="B3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="58"/>
                    <count group_id="B2" value="59"/>
                    <count group_id="B3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.56" lower_limit="44.38" upper_limit="79.39"/>
                    <measurement group_id="B2" value="66.63" lower_limit="44.68" upper_limit="81.98"/>
                    <measurement group_id="B3" value="65.53" lower_limit="44.38" upper_limit="81.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="58"/>
                    <count group_id="B2" value="59"/>
                    <count group_id="B3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Denmark</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="58"/>
                    <count group_id="B2" value="59"/>
                    <count group_id="B3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Local Failure Free Survival</title>
        <description>Local failure free survival 9 month after first RT treatment measured by CT/FDG-CT</description>
        <time_frame>9 months</time_frame>
        <population>Analyzed as intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>B: 66Gy/33F+Navelbine Oral 150 mg q3w</title>
            <description>Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks).&#xD;
Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization&#xD;
Navelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks&#xD;
66 Gy/33F: irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)</description>
          </group>
          <group group_id="O2">
            <title>A: 60Gy/30F+Navelbine Oral 150 mg q3w</title>
            <description>Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks) Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization&#xD;
Navelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks&#xD;
60 Gy/30F: irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Local Failure Free Survival</title>
          <description>Local failure free survival 9 month after first RT treatment measured by CT/FDG-CT</description>
          <population>Analyzed as intention to treat</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="2.8" upper_limit="67"/>
                    <measurement group_id="O2" value="9.9" lower_limit="2.6" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Early Toxicity to Concurrent Vinorelbine and Radiotherapy</title>
        <time_frame>9 months</time_frame>
        <population>Dysphagia, weight loss ≥20%, pulmonary toxicity grade 3, leucopenia grade 3 or higher</population>
        <group_list>
          <group group_id="O1">
            <title>B: 66Gy/33F+Navelbine Oral 150 mg q3w</title>
            <description>Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks).&#xD;
Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization&#xD;
Navelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks&#xD;
66 Gy/33F: irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)</description>
          </group>
          <group group_id="O2">
            <title>A: 60Gy/30F+Navelbine Oral 150 mg q3w</title>
            <description>Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks) Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization&#xD;
Navelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks&#xD;
60 Gy/30F: irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Early Toxicity to Concurrent Vinorelbine and Radiotherapy</title>
          <population>Dysphagia, weight loss ≥20%, pulmonary toxicity grade 3, leucopenia grade 3 or higher</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dysphagia g3+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary tox</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leucopenia g3+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Local Tumour Control</title>
        <description>Loco-regional control</description>
        <time_frame>9 months</time_frame>
        <posting_date>09/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival, death of any cause</description>
        <time_frame>72 months</time_frame>
        <population>Overall survival, intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>B: 66Gy/33F+Navelbine Oral 150 mg q3w</title>
            <description>Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks).&#xD;
Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization&#xD;
Navelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks&#xD;
66 Gy/33F: irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)</description>
          </group>
          <group group_id="O2">
            <title>A: 60Gy/30F+Navelbine Oral 150 mg q3w</title>
            <description>Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks) Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization&#xD;
Navelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks&#xD;
60 Gy/30F: irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival, death of any cause</description>
          <population>Overall survival, intention to treat</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" lower_limit="3.0" upper_limit="68"/>
                    <measurement group_id="O2" value="23.3" lower_limit="3.2" upper_limit="65.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Late Toxicity</title>
        <description>Late toxicity related to concurrent Vinorelbine and radiotherapy</description>
        <time_frame>36 months</time_frame>
        <posting_date>09/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Free Survival</title>
        <description>Disease free survival, death of any cause</description>
        <time_frame>72 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>B: 66Gy/33F+Navelbine Oral 150 mg q3w</title>
            <description>Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks).&#xD;
Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization&#xD;
Navelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks&#xD;
66 Gy/33F: irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)</description>
          </group>
          <group group_id="O2">
            <title>A: 60Gy/30F+Navelbine Oral 150 mg q3w</title>
            <description>Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks) Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization&#xD;
Navelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks&#xD;
60 Gy/30F: irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival</title>
          <description>Disease free survival, death of any cause</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" lower_limit=".2" upper_limit="68"/>
                    <measurement group_id="O2" value="8.8" lower_limit=".2" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years, death or recurrence</time_frame>
      <group_list>
        <group group_id="E1">
          <title>B: 66Gy/33F+Navelbine Oral 150 mg q3w</title>
          <description>Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks).&#xD;
Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization&#xD;
Navelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks&#xD;
66 Gy/33F: irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)</description>
        </group>
        <group group_id="E2">
          <title>A: 60Gy/30F+Navelbine Oral 150 mg q3w</title>
          <description>Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks) Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization&#xD;
Navelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks&#xD;
60 Gy/30F: irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrilation</sub_title>
                <description>Atrial flutter</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <description>Dysphagia, esophagitis, stenosis, obstipation, nausea</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="58"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <description>Pneumonitis, pneumonia, embolus</description>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="58"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Herpes zoster</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary toxicity</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="58"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Olfred Hansen, Professor, Ph.D.</name_or_title>
      <organization>Dept. Oncology, Odense University Hospital</organization>
      <phone>+4524241588</phone>
      <email>olfred.hansen@rsyd.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

